The pharmacokinetic profile of nimesulide in healthy volunteers
- PMID: 7506196
- DOI: 10.2165/00003495-199300461-00013
The pharmacokinetic profile of nimesulide in healthy volunteers
Abstract
After oral administration of nimesulide 100mg in tablet, granule or suspension to healthy volunteers, the drug was rapidly and extensively absorbed. Mean peak plasma concentrations of 2.86 to 4.58 mg/L were achieved within 1.22 to 3.83 hours of administration. The presence of food did not reduce either the rate or the extent of nimesulide absorption. When administered in suppository form, nimesulide peak plasma concentrations were lower and occurred later than those achieved after oral administration; the bioavailability of nimesulide given by suppository ranged from 54 to 96%, relative to that of orally administered formulations. Nimesulide is rapidly distributed, principally throughout the extracellular fluid compartment; values for volume of distribution ranged from 0.19 to 0.39 L/kg. Nimesulide is extensively bound to plasma proteins: at concentrations ranging from 0.5 to 10 mg/L, the unbound fraction varied between 0.7 and 4.0%. With oral administration, nimesulide concentrations decline monoexponentially following peak levels. The estimated mean terminal half-life for nimesulide varied from 1.96 to 4.73 hours. Excretion of unchanged drug in urine and faeces is negligible. Nimesulide is mainly eliminated by metabolic transformation and the principal metabolite is the 4'-hydroxy derivative. The presence of other metabolites is being evaluated. Excretion of nimesulide metabolites in the urine and faeces accounts for about 80 and 20% of the administered dose, respectively. Total plasma clearance of nimesulide was 39.7 to 90.9 ml/h/kg, reflecting almost exclusive metabolic clearance. The drug has a low extraction ratio, close to 0.1. Differences in gender have only a limited influence on the pharmacokinetic profile of nimesulide and its hydroxylated metabolite. With twice-daily administration of nimesulide 100 mg (tablets) or 200mg (suppositories), steady-state is achieved within 24 to 36 hours (2 to 3 administrations). With oral nimesulide 100mg twice daily, only modest accumulation of nimesulide and its 4'-hydroxy derivative occurs (Rmin, 1.59 for nimesulide and 1.46 for the hydroxylated metabolite).
Similar articles
-
Clinical pharmacokinetics of nimesulide.Clin Pharmacokinet. 1998 Oct;35(4):247-74. doi: 10.2165/00003088-199835040-00001. Clin Pharmacokinet. 1998. PMID: 9812177 Review.
-
A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers.Vojnosanit Pregl. 2005 Dec;62(12):887-93. doi: 10.2298/vsp0512887j. Vojnosanit Pregl. 2005. PMID: 16375216 Clinical Trial.
-
Clinical and pharmacokinetic study of nimesulide in children.Drugs. 1993;46 Suppl 1:215-8. doi: 10.2165/00003495-199300461-00055. Drugs. 1993. PMID: 7506175 Clinical Trial.
-
Effect of age and disease on the pharmacokinetics of nimesulide.Drugs. 1993;46 Suppl 1:73-8. doi: 10.2165/00003495-199300461-00014. Drugs. 1993. PMID: 7506197 Review.
-
Pharmacokinetics and bioavailability of nimesulide in goats.J Vet Pharmacol Ther. 2007 Apr;30(2):157-62. doi: 10.1111/j.1365-2885.2007.00838.x. J Vet Pharmacol Ther. 2007. PMID: 17348902
Cited by
-
Liposomal Aloe vera trans-emulgel drug delivery of naproxen and nimesulide: A study.Int J Pharm Investig. 2015 Jan-Mar;5(1):28-34. doi: 10.4103/2230-973X.147230. Int J Pharm Investig. 2015. PMID: 25599030 Free PMC article.
-
Alzheimer's Disease: Cellular and Pharmacological Aspects.Geriatrics (Basel). 2024 Jun 22;9(4):86. doi: 10.3390/geriatrics9040086. Geriatrics (Basel). 2024. PMID: 39051250 Free PMC article. Review.
-
Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions.Pharmaceuticals (Basel). 2010 Jun 14;3(6):1949-1965. doi: 10.3390/ph3061949. Pharmaceuticals (Basel). 2010. PMID: 27713336 Free PMC article. Review.
-
Clinical pharmacokinetics of nimesulide.Clin Pharmacokinet. 1998 Oct;35(4):247-74. doi: 10.2165/00003088-199835040-00001. Clin Pharmacokinet. 1998. PMID: 9812177 Review.
-
Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.Br J Pharmacol. 1999 Apr;126(8):1824-30. doi: 10.1038/sj.bjp.0702518. Br J Pharmacol. 1999. PMID: 10372826 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources